OptiBiotix Health

OptiBiotix Health EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OptiBiotix Health (OPTI.L) as of Nov 11, 2026 is -3.13 M GBP. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -2.06 M GBP — a change of 52.26% (lower).

EBITDA

-3.13 MGBP

YoY

52.26%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OptiBiotix Health is 2025 -3.13 M GBP. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OptiBiotix Health was 2024 -2.06 M GBP. It decreases by 52.26% lower compared to the previous year.

The OptiBiotix Health EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.36 M GBP
Jan 1, 2019
-1.95 M GBP
Jan 1, 2020
6.00 M GBP
Jan 1, 2021
6.51 M GBP
Jan 1, 2022
2.67 M GBP
Jan 1, 2023
-1.49 M GBP
Jan 1, 2024
-2.06 M GBP
Jan 1, 2025
-3.13 M GBP
The OptiBiotix Health EBITDA history
YEAREBITDAYoY
-3.13 MGBP+52.26%
-2.06 MGBP+38.05%
-1.49 MGBP-155.91%
2.67 MGBP-59.08%
6.51 MGBP+8.50%
6.00 MGBP-407.99%
-1.95 MGBP+43.62%
-1.36 MGBP-174.77%
1.82 MGBP-229.44%
-1.40 MGBP+7.10%
-1.31 MGBP+167.73%
-489,000.00GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiBiotix Health Stock analysis

What does OptiBiotix Health do? OptiBiotix Health Plc is a British company founded in 2012 that focuses on the development and marketing of pre- and probiotic products. The company's goal is to improve the health and well-being of people around the world. OptiBiotix Health has developed a unique business model based on identifying new applications for existing nutrients and probiotic bacteria. The company works closely with leading academic institutions to develop innovative technologies and products based on scientific knowledge and clinical studies. An important division of the company is weight management products. OptiBiotix Health has developed a promising approach based on the identification of bacterial strains that can reduce the growth of fat cells and improve metabolism in the body. These bacteria can be found in products such as "SlimBiome," "GoFigure," and "CholBiome." Another area covered by OptiBiotix Health is gastroenterology. The Bonne Santé products include vitamin-rich, fiber-rich, and lactic acid bacteria-rich foods and beverages that keep the digestive system healthy and promote well-being. By using probiotics and prebiotics, the company can also offer products for people with digestive disorders and conditions such as irritable bowel syndrome. OptiBiotix Health also has a health monitoring and diagnostics department that focuses on the discovery of biomarker-based tests. These tests can be used to detect specific diseases and predict the course of diseases. Some of the key products being developed here are "SweetBiotix" and "CardioBiotix." These products aim to reduce the risk of type 2 diabetes and cardiovascular diseases as part of the life science portfolio. OptiBiotix Health's products are distributed worldwide. The company has various agreements with leading manufacturers and distribution partners in Europe, Asia, and North America. In addition to marketing its own products, the company also offers technologies and expertise for the development and marketing of probiotic and prebiotic products. OptiBiotix Health has solidified its successes by winning a number of awards. In 2019, the company won the Health Investor award for "Pharma/Technology Deal of the Year" for its partnership with Seed Health LLC, and in 2020, its online group "OptiBiotix Health PLC Forum" was nominated for the "Best Informative Forum Award" at the British Online Awards. The vision of OptiBiotix Health is to improve the health and well-being of people by developing and marketing innovative and effective products and technologies. The company is committed to scientific thinking and continuous innovation to fully harness the potential of probiotic and prebiotic products. OptiBiotix Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiBiotix Health stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OptiBiotix Health is -3.13 M GBP in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OptiBiotix Health changed from -2.06 M GBP to -3.13 M GBP, representing a 52.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) OptiBiotix Health since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s OptiBiotix Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — OptiBiotix Health

All Key Metrics — OptiBiotix Health